After a Setback, Gene Therapy Progresses ... Gingerly
Level 5 - mechanism / opinion, no new human data
Narrative news and commentary article without primary empirical human data.
OpenAlex W1605974936 · doi:10.1126/science.291.5509.1692
What was done
This is a narrative news commentary published in Science discussing the ongoing progress, controversies, and regulatory environment of clinical gene therapy research, focusing on hemophilia, in the aftermath of the 1999 death of Jesse Gelsinger.
What was found
The abstract reports no numerical data, trial statistics, or specific clinical measurements. It qualitatively notes that encouraging clinical results have emerged over the prior year, especially for hemophilia, amidst strict regulatory oversight and ongoing safety concerns.
Why it matters
It documents a key historical transitional period in gene therapy when emerging clinical efficacy in conditions like hemophilia had to be balanced against heightened regulatory scrutiny and safety standards.
Limits
The record is a journalistic summary rather than a clinical trial or systematic review. It contains no primary data, patient sample sizes, specific trial methodologies, or quantitative outcome measures.
Cited by
- supports A patient's death during an early gene therapy clinical trial significantly delayed and set back the development of the gene therapy field.